The Trump administration is implementing policies to negotiate fairer drug pricing with wealthy allies, aiming to reduce subsidies for other countries and incentivize pharmaceutical innovation that benefits American patients. Recent successes include a deal with the UK to reform drug pricing practices, which is expected to lead to more balanced global pricing, increased sales opportunities for American firms, and greater investment in developing new treatments. The article also briefly touches on the significant advancements in cancer treatment through immunotherapies.
By pushing other wealthy allies to reform their drug-pricing practices, the White House is working to more evenly share the burden of funding the research and development that benefits the entire world.is long overdue. And it’ll greatly benefit American patients and workers, so long as the administration holds firm in the face of inevitable resistance from trading partners and left-wing ideologues.
In December, the Trump administration notched its first major victory in this effort to restore fairness. It compelled the United Kingdom toon medicines as a share of GDP, largely by reducing the revenue it claws back from drug companies and by raising the threshold it uses to decide whether a new drug is worth the cost. This deal, and the other similar ones that top administration officials have promised will come soon, will do more than ease pressure on American patients today. It’ll help spur breakthroughs tomorrow.
More balanced global pricing means that American firms will have more sales opportunities abroad. And the promise of increased revenues will incentivize companies to take the enormous risks required to develop new treatments.
It works by attacking not just tumors, but healthy cells as well, leading to harsh side effects and limited long-term success against the most advanced stages of the disease. Immunotherapies changed the game. Instead of broadly attacking the body, they help the immune system distinguish between healthy cells and cancerous ones — and target only the tumors. Today, millions of patients have taken immunotherapies to treat a wide variety of cancers. Many people who were previously told they’d be dead within months are still alive well over a decade later.
Nine out of 10 drugs that enternever make it to patients. The few that succeed must generate sufficient returns to cover the cost of all those failed research projects, fund the next wave of innovation, and reward investors for taking those huge risks.
The administration’s recent efforts are a step in the right direction. The U.S. government is finally upending a status quo that has quietly shifted costs onto its own citizens for decades. Immunotherapies show what scientists can achieve when companies have the incentives to take risks and invest in research. If we want more breakthroughs like these, we need a system where America leads in developing new treatments and where other countries pay fair prices for the fruits of that research.
Drew Johnson is a government watchdog and health policy analyst who was the Trump-endorsed Republican nominee for the U.S. House of Representatives in Nevada’s 3rd congressional district in 2024.
Trump signs order boosting psychedelic drugs for PTSD with Rogan looking onVirginia could lose influence in Congress if Spanberger’s gerrymander passesWashington talks energy dominance. Without permitting reform, it can’t build
Drug Pricing Global Health Pharmaceutical Innovation Trump Administration Immunotherapy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Trump Administration Claims Historic Tax Cuts Benefit Americans, Criticizes DemocratsThe Trump White House asserts that President Trump's tax cuts have provided significant financial relief to Americans, returning thousands of dollars to taxpayers and benefiting millions of families and small businesses. They contrast this with what they describe as Democrats' alleged intention to impose major tax hikes, labeling them as 'affordability frauds'.
Read more »
Acting ICE Director Todd Lyons Resigns Amid Trump Administration's Deportation PushTodd Lyons, the acting director of U.S. Immigration and Customs Enforcement (ICE) and a central figure in President Donald Trump's mass deportation efforts, has submitted his resignation. Federal officials announced his departure on Thursday. Lyons cited a desire to spend more time with his family as the reason for his resignation in his letter to Homeland Security Secretary Markwayne Mullin. Mullin and White House spokesperson Abigail Jackson both praised Lyons' leadership and contributions to national security and public safety.
Read more »
Trump administration sets first oil and gas lease sale in Alaska’s wildlife refugeUnder the One Big Beautiful Bill passed last summer, BLM is required to conduct at least four lease sales in Alaska's Coastal Plain by 2035.
Read more »
ICE Acting Director Todd Lyons Resigns Amidst Trump Administration's Immigration PoliciesTodd Lyons, a key figure in implementing President Donald Trump's mass deportation agenda as the acting director of U.S. Immigration and Customs Enforcement (ICE), has resigned. Federal officials announced his departure on Thursday, with Lyons citing family reasons for his decision. Secretary Markwayne Mullin praised Lyons' leadership in strengthening national security and public safety by removing dangerous individuals from communities. Lyons' tenure saw a significant number of deportations, and he previously served in the U.S. Air Force special forces. Public perception of ICE has remained largely unfavorable during his leadership.
Read more »
Pete Hegseth’s shallow theatrics are damaging the Trump administrationWar Secretary Pete Hegseth must end his ranting hyperbole. He undermines military professionalism and the Trump administration's credibility.
Read more »
House Democrat asks Trump administration to loosen restrictions on sea lion euthanasiaMarie Gluesenkamp Perez penned a letter warning that sea lions are wreaking havoc on her district's fishing industry.
Read more »